Biopharmaceutical company CSL Behring has dosed the first patient in part 3 of its Affinity clinical trial programme, a Phase I/III pivotal study evaluating recombinant single-chain factor VIII (rVIII-SingleChain) for the treatment of haemophilia A.
The open-label, non-randomised multi-centre study is designed to assess the efficacy, safety and pharmacokinetic profile of rVIII-SingleChain versus recombinant human antihemophilic factor VIII (octocog alpha).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
CSL global clinical research and development senior vice president Dr Russell Basser said; "As part of our ongoing commitment to the hemophilia community, we are developing and investigating innovative recombinant factor therapies for the treatment of both hemophilia A and B that have the potential to offer patients and caregivers significant advances in treatment and convenience of factor infusion."
A total of 27 subjects in the part 1 of the study were administered with a single infusion of 50IU/kg body weight (bw) of octocog alfa subsequent to a single infusion of 50IUkg bw rVIII-SingleChain.
At a dose and frequency determined by the study doctor based on underlying bleeding phenotype, the subjects in parts 2 and 3 of the study will be given infusions of rVIII-SingleChain to prevent and treat bleeding.
With a novel recombinant single-chain factor VIII design, rVIII-SingleChain leverages a strong, covalent bond to connect light and heavy chains to improve the stability and half-life of factor VIII (FVIII).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
